Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Soligenix Inc SNGX

Healthcare Biotechnology

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe... see more

Add To Watchlist

Recent & Breaking News (NDAQ:SNGX)

Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

PR Newswire May 24, 2024

Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split

PR Newswire May 23, 2024

SuVax(TM) and MarVax(TM) Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference

PR Newswire May 21, 2024

Soligenix Encourages Stockholders to Vote Prior to Annual Meeting

PR Newswire May 20, 2024

Positive Clinical Results from HyBryte(TM) Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice

PR Newswire May 16, 2024

Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results

PR Newswire May 10, 2024

Soligenix to Present at Upcoming Conferences

PR Newswire May 6, 2024

Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa

PR Newswire April 25, 2024

Soligenix Announces Pricing of $4.75 Million Public Offering

PR Newswire April 18, 2024

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection

PR Newswire April 15, 2024

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection

PR Newswire April 11, 2024

Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte(TM) With the European Medicines Agency

PR Newswire April 3, 2024

Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results

PR Newswire March 15, 2024

Soligenix Announces Formation of Behçet's Disease Medical Advisory Board

PR Newswire February 8, 2024

Soligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Accesswire January 26, 2024

Soligenix to Present at The Microcap Conference

PR Newswire January 25, 2024

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease

PR Newswire January 8, 2024

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

PR Newswire January 4, 2024

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses

PR Newswire January 2, 2024

"HyBryte(TM) Use in Early-Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug Discovery

PR Newswire December 1, 2023